Saliva swab may predict liver risk in leukemia patients
NCT ID NCT03568266
First seen Jan 11, 2026 · Last updated Jun 22, 2026 · Updated 28 times
Summary
This study collects saliva samples from 500 people with newly diagnosed acute lymphoblastic leukemia to look for genetic markers linked to liver damage from the drug asparaginase. The goal is to better understand why some patients develop liver problems during treatment. No new drugs are being tested; the study simply observes and analyzes genetic information.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Los Angeles General Medical Center
RECRUITINGLos Angeles, California, 90033, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
USC / Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could help doctors identify which patients are at risk for liver damage from asparaginase, allowing for safer, personalized treatment plans.
What could go wrong
This is an early-stage pilot study focused on observation, not treatment. It may not find clear genetic markers, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.